Gain Therapeutics Inc (GANX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $46.31M
Last updated: Nov 17, 2026 at 11:06 AM ET
Gain Therapeutics Inc (GANX) Earnings: Report Dates and Results
Gain Therapeutics (GANX) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Gain Therapeutics reported EPS of -$0.07, above the -$0.13 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GANX has an expected report date of Mar 24, 2027.
Earnings History
Of the 23 quarters below that had an estimate, GANX beat 12, missed 10 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 284.62% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.07 | -$0.13 | -$0.13 - -$0.12 | +46.15% | Beat | N/A | 4 | 0 up, 0 down | Nov 10, 2026 | N/A |
| Jun 30, 2026 | -$0.11 | -$0.14 | -$0.18 - -$0.13 | +21.43% | Beat | N/A | 4 | 0 up, 0 down | Aug 11, 2026 | N/A |
| Mar 31, 2026 | -$0.13 | -$0.14 | -$0.15 - -$0.13 | +7.14% | Beat | N/A | 3 | 2 up, 0 down | May 11, 2026 | N/A |
| Dec 31, 2025 | -$0.11 | -$0.14 | -$0.15 - -$0.12 | +23.77% | Beat | N/A | 4 | 1 up, 0 down | Mar 26, 2026 | N/A |
| Sep 30, 2025 | -$0.15 | -$0.15 | -$0.16 - -$0.14 | 0.00% | In line | N/A | 3 | 2 up, 1 down | Nov 12, 2025 | N/A |
| Jun 30, 2025 | -$0.19 | -$0.17 | N/A | -11.76% | Miss | N/A | 5 | 2 up, 1 down | Aug 12, 2025 | N/A |
| Mar 31, 2025 | -$0.16 | -$0.17 | -$0.22 - -$0.14 | +5.88% | Beat | N/A | 4 | 1 up, 0 down | May 14, 2025 | N/A |
| Dec 31, 2024 | -$0.08 | -$0.19 | -$0.23 - -$0.17 | +57.33% | Beat | N/A | 4 | 2 up, 0 down | Mar 27, 2025 | $82242 |
| Sep 30, 2024 | -$0.17 | -$0.21 | -$0.23 - -$0.18 | +19.05% | Beat | N/A | 3 | 1 up, 0 down | Nov 14, 2024 | N/A |
| Jun 30, 2024 | -$0.42 | -$0.22 | -$0.23 - -$0.16 | -90.91% | Miss | N/A | 3 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.22 | -$0.33 | -$0.39 - -$0.19 | +33.33% | Beat | N/A | 4 | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.36 | -$0.32 | -$0.40 - -$0.26 | -12.50% | Miss | N/A | 4 | 0 up, 0 down | Mar 26, 2024 | $64800 |
| Sep 30, 2023 | -$0.37 | -$0.46 | -$0.51 - -$0.38 | +19.57% | Beat | N/A | 5 | 0 up, 0 down | Nov 14, 2023 | N/A |
| Jun 30, 2023 | -$0.62 | -$0.38 | -$0.41 - -$0.10 | -63.16% | Miss | N/A | 4 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.43 | -$0.39 | -$0.41 - -$0.37 | -10.26% | Miss | N/A | 3 | 0 up, 0 down | May 12, 2023 | $55180 |
| Dec 31, 2022 | -$0.39 | -$0.36 | -$0.42 - -$0.33 | -8.33% | Miss | N/A | 4 | 0 up, 0 down | Mar 23, 2023 | $140108 |
| Sep 30, 2022 | -$0.38 | -$0.46 | -$0.54 - -$0.39 | +17.39% | Beat | N/A | 4 | 0 up, 0 down | Nov 10, 2022 | N/A |
| Jun 30, 2022 | -$0.43 | -$0.31 | -$0.33 - -$0.29 | -38.71% | Miss | N/A | 3 | 1 up, 0 down | Aug 8, 2022 | $95102 |
| Mar 31, 2022 | -$0.28 | -$0.37 | -$0.43 - -$0.28 | +24.32% | Beat | N/A | 4 | 1 up, 0 down | May 16, 2022 | $45006 |
| Dec 31, 2021 | -$0.26 | -$0.49 | -$0.51 - -$0.47 | +46.94% | Beat | N/A | 3 | 0 up, 0 down | Mar 24, 2022 | $70552 |
| Sep 30, 2021 | -$0.39 | -$0.33 | -$0.40 - -$0.28 | -18.18% | Miss | N/A | 2 | 2 up, 0 down | Nov 12, 2021 | N/A |
| Jun 30, 2021 | -$0.30 | -$0.23 | N/A | -30.43% | Miss | N/A | 2 | N/A | Aug 11, 2021 | $89173 |
| Mar 31, 2021 | -$0.50 | -$0.13 | N/A | -284.62% | Miss | N/A | 2 | N/A | May 10, 2021 | $5269 |
| Dec 31, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Mar 22, 2021 | $9139 |
| Sep 30, 2020 | -$0.41 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | $6696 |
| Sep 30, 2019 | -$0.32 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | $10325 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.61, after -$0.89 the year before. It was -$0.73 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.61 | N/A |
| Dec 31, 2024 | -$0.89 | N/A |
| Dec 31, 2023 | -$1.78 | N/A |
| Dec 31, 2022 | -$1.48 | N/A |
| Dec 31, 2021 | -$1.45 | N/A |
| Dec 31, 2020 | -$0.73 | N/A |
Frequently Asked Questions About GANX
When is Gain Therapeutics's next earnings date?
Gain Therapeutics's next earnings report is expected for Mar 24, 2027.
Did GANX beat earnings estimates last quarter?
Yes. Gain Therapeutics reported EPS of -$0.07 for the quarter ended Sep 30, 2026, above the -$0.13 estimate, a 46.15% surprise.
What EPS do analysts expect from GANX next quarter?
The consensus EPS estimate for Gain Therapeutics for the quarter ending Dec 31, 2026 is -$0.13 from 6 analysts, with estimates from -$0.16 to -$0.08.
How often does GANX beat earnings estimates?
Gain Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +18.74%.
GANX pages: Overview, Earnings, Forecast, Financials, Competitors